Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim
- 17 Nov 2017 This trial has been completed in Hungary ( End Date: 2017-11-01).
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 10 Oct 2017 Planned End Date changed from 1 Oct 2017 to 13 Oct 2017.